# Association between gastroesophageal reflux disease and metabolic syndrome: a bidirectional two-sample Mendelian randomization analysis

Tao He<sup>1</sup>, Xiaoling Geng<sup>1</sup>, Xue Lin<sup>2</sup>, Yufei Li<sup>1</sup>, Zhijun Duan<sup>1\*</sup>

<sup>1</sup>Department of Gastroenterology, The First Affiliated Hospital of Dalian Medical University, Dalian, China

<sup>2</sup>Department of Digestive Endoscopy, Central Hospital of Dalian University of Technology, Dalian, Dalian, China

Submitted: 26 June 2024; Accepted: 25 September 2024 Online publication: 22 October 2024

Arch Med Sci 2024; 20 (5): 1715–1719 DOI: https://doi.org/10.5114/aoms/193708 Copyright © 2024 Termedia & Banach

Gastroesophageal reflux disease (GERD), characterized primarily by regurgitation and recurrent heartburn, is predominantly caused by esophageal disorders such as peptic strictures, reflux esophagitis, and Barrett's esophagus [1]. In recent years, changes in living standards, lifestyle, and dietary habits have contributed to the increased prevalence of GERD. This condition not only diminishes quality of life for sufferers but also significantly increases healthcare resource utilization and economic burden [2]. Therefore, it is crucial to implement preventative measures to reduce the risk of GERD development.

Metabolic syndrome (MetS) encompasses a range of metabolic abnormalities, including hypertension, hyperglycemia, hypoalphalipoproteinemia, hypertriglyceridemia, and abdominal obesity [3, 4]. The incidence of MetS is rising globally [5]. Although several observational studies have identified positive correlations between GERD risk and MetS incidence [6, 7], these associations may be influenced by factors such as short follow-up periods, limited sample sizes, confounders, and reverse causation [8]. Thus, further analysis is necessary to determine the causal relationship between MetS and the risk of GERD development.

In this study, we conducted univariable Mendelian randomization (UVMR) and multivariable Mendelian randomization (MVMR) analyses to investigate the causal relationship between MetS, its components, and the risk of GERD development. Additionally, sensitivity analyses were performed to assess the impact of assumptions and the robustness of the results.

**Methods.** *Study design:* This research utilized a bidirectional two-sample Mendelian randomization (MR) analysis to investigate the causal relationship between MetS and its components with GERD risk [9]. By employing single nucleotide polymorphisms (SNPs) as instrumental variables, MR can reveal causality between specific exposures and outcomes [8]. This approach leverages the principle that genetic variant allocation follows Mendel's second law, ensuring randomization and making MR comparable to a randomized controlled trial. This design is crucial for minimizing confounders and reverse causality inherent in observational studies, thereby enhancing the reliability of the results [10].

**Data sources:** Exposure: Data for MetS and its components were obtained from summary statistics of comprehensive genome-wide association studies (GWAS) conducted on MetS (n = 291,107), triglycerides (TG)

#### \*Corresponding author:

Zhijun Duan PhD Department of Gastroenterology The First Affiliated Hospital of Dalian Medical University Dalian 116000, China Phone: 86-83635963 E-mail: cathydoctor@sina.com



Attribution-NonCommercial-ShareAlike 4.0 International (CC BY -NC -SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)

Creative Commons licenses: This is an Open Access article distributed under the terms of the Creative Commons

(n = 441,016), and high-density lipoprotein (HDL) (n = 403,943) from the UK Biobank [11, 12]; body mass index (BMI) (n = 461,460), hypertension (n =463,010), waist circumference (WC) (n = 462,166), and type 2 diabetes (T2D) (n = 461,578) from the Medical Research Council Integrative Epidemiology Unit (MRC-IEU); fasting blood glucose (FBG) (n = 58,074) from the Glucose and Insulin-Related Traits Consortium (MAGIC) [13]; and diastolic blood pressure (DBP) (n = 757,601) and systolic blood pressure (SBP) (n = 757,601) from the International Consortium of Blood Pressure [14].

*Outcome:* GERD data were obtained from a GWAS conducted by the MRC-IEU, involving 473,524 healthy controls and 129,080 GERD patients [15].

MR analyses: A genome-wide significance threshold of  $p < 5 \times 10^{-8}$  was applied for selecting instrumental variables (IVs). SNPs exhibiting linkage disequilibrium (LD) ( $r^2 < 0.001$ ) within a 10 million base-pair region were excluded, retaining only independent SNPs [16]. In cases where the GWAS data lacked corresponding outcome SNPs, proxy SNPs in LD ( $r^2 > 0.8$ ) were used. We manually reviewed the harmonized data and excluded SNPs strongly associated with the outcome (p < $1 \times 10^{-5}$ ). After excluding SNPs with strong outcome associations, bidirectional MR analysis was conducted. IVs with an F-statistic > 10 were considered robust [17]. The F-statistic was calculated using the formula:  $F = [(N - k - 1)/k] \times [R^2/(1 - R^2)]$ , where N represents the sample size, k the total number of SNPs, and  $R^2$  the proportion of variance explained by the IVs. PhenoScanner V2 was employed to identify other genome-wide significant traits associated with the SNPs that could serve as confounding factors [18].

The inverse variance weighted (IVW) method was the primary analysis tool for estimating causal effects [19]. Sensitivity analyses included MR-Egger, weighted median, and weighted mode approaches [20]. Heterogeneity was assessed using Cochran's Q statistic (p < 0.05). Potential outliers were identified through leave-one-out analysis and forest plots, while horizontal pleiotropy was detected using the MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) and MR-Egger intercept tests [21]. MR-PRESSO was also used to evaluate the influence of identified outliers on MR results, followed by MR analysis post-outlier removal [22].

Additionally, we employed multivariable Mendelian randomization (MVMR)-IVW method to validate significant causal relationships identified in the UVMR analysis, ensuring adjustments for potential confounding factors associated with MetS, BMI, WC, hypertension, HDL, TG, and T2D.

*Statistical analysis:* Statistical analyses were performed using the R packages (v4.2.2) "Mendelian Randomization", "MR-PRESSO" and "TwoSam-

pleMR" with two-sided *p*-values < 0.05 considered statistically significant.

Results. The SNPs related to MetS, its components, and GERD are detailed in Supplementary Tables SI and SII. Using the IVW method, we identified significant causal associations between GERD risk and several factors, including waist circumference, BMI, type 2 diabetes, hypertension, TG, MetS, and HDL cholesterol. The respective odds ratios (OR) were 2.166, 2.160, 1.951, 1.908, 1.135, 1.034, and 0.944, with corresponding 95% confidence intervals (CIs) of 1.972-2.270, 2.033-2.295, 1.074-3.545, 1.135-3.206, 1.071-1.203, 1.002-1.068, and 0.896-0.994, all with associated *p*-values < 0.001. However, no significant causal associations were found between GERD risk and FBG, SBP, or DBP, with respective ORs of 1.043, 1.002, and 0.997, corresponding 95% CIs of 0.963-1.131, 0.999-1.005, and 0.991-1.003, and *p*-values of 0.302, 0.196, and 0.332.

Significant heterogeneity was observed for all traits except MetS (p = 0.498), HDL (p = 0.158), T2D (p = 0.528), and FBG (p = 0.386), but no pleiotropy was detected. Additionally, the MR-PRESSO test did not identify any distorted effect outliers (Figure 1 A). Supplementary Figures S1–S10 display the significant causal effects between MetS, its components, and GERD risk using leave-oneout, forest, funnel, and scatter plots.

In the reverse analysis, the IVW method revealed significant causal relationships between GERD risk and MetS, BMI, WC, DBP, SBP, hypertension, HDL, TG, T2D, and FBG. The respective ORs were 1.765, 1.454, 1.324, 1.378, 1.973, 1.053, 0.433, 1.187, 1.026, and 1.033, with corresponding 95% Cls of 1.623-1.919, 1.363-1.550, 1.258-1.393, 1.135-1.672, 1.415-2.749, 1.045-1.062, 0.816-0.851, 1.159-1.215, 1.020-1.032, and 1.007–1.060, all with *p*-values < 0.001. Significant heterogeneity was observed for all traits except FBG (p = 0.737), with no significant horizontal pleiotropy (p > 0.05), as indicated by the MR-Egger intercept test (Figure 1 B). Supplementary Figures S11-S20 display the significant causal effects between GERD and MetS and its components using leave-one-out, forest, funnel, and scatter plots.

MVMR analysis revealed that among the MetS components, BMI (OR = 2.103; 95% CI: 1.752–2.525;  $p = 1.60E^{-15}$ ) and hypertension (OR = 5.087; 95% CI: 3.109–8.324;  $p = 9.51E^{-11}$ ) were positively associated with the risk of GERD development (Figure 2).

**Discussion.** The this study, we evaluated the effects of MetS and its components on the risk of GERD development using MR analysis. The UVMR analysis demonstrated that MetS, WC, BMI, hypertension, HDL, TG, and T2D were associated with GERD risk, whereas DBP, SBP, and FBG did not show

a causal relationship with GERD. Interestingly, reverse MR analysis revealed causal associations between GERD and both DBP and SBP. Furthermore, MVMR analysis identified BMI and hypertension as having a causal relationship with GERD. Sensitivity analysis confirmed the absence of horizontal pleiotropy, reinforcing the robustness of our findings.

Adipose tissue in individuals with obesity is metabolically active, producing various inflammatory cytokines that contribute to systemic chronic inflammation, which can promote the development of GERD [23]. The link between obesity and GERD has been well established in numerous epidemiological studies [24]. Obesity contributes to insulin resistance, leading to a cascade of metabolic abnormalities that are key determinants of MetS [25]. This complexity makes it challenging to discern whether obesity alone is causally involved in GERD or if obesity, along with its associated metabolic disorders, col-

Α

lectively contributes to GERD development. Epidemiological evidence suggests that MetS is significantly associated with an increased risk of GERD [26]. For example, a cross-sectional study (n = 372) found that patients with MetS had a higher incidence of reflux esophagitis (RE) [27]. Additionally, a meta-analysis of 15 cohorts (n = 103,048) indicated that MetS may independently serve as a risk factor for GERD [28]. Consistent with these findings, our bidirectional MR analysis revealed a highly significant bidirectional causal association between MetS and GERD risk.

However, our study has certain limitations. First, our research was conducted within a European population, which may limit the generalizability of our findings to other ethnic groups. Second, we were unable to perform stratified analyses based on gender and age due to the lack of individual-level data, underscoring the need for further comprehensive prospective studies. Lastly, while MR analysis provides

Exposure	SNPs	Methods	P-value		OR (95% CI)	Heterogeneity. p-val	Pleiotropy. <i>p</i> -val
Metabolic	24	MR-Egger	2.55e-01	H <mark>e</mark> H	1.050 (0.967 to 1.141)	4.48e-01	0.696
syndrome	24	IVW	3.76e-02	•	1.034 (1.002 to 1.068)	4.98e-01	
-	24	Weighted-median	4.30e-01	N <mark>e</mark> r	1.020 (0.971 to 1.071)		
	24	MR-Presso	4.61e-02		1.034 (1.002 to 1.067)		
BMI	159	MR-Egger	5.84e-09	<b>⊢_</b> ●>	• 1.862 (1.528 to 2.270)	2.26e-05	0.125
	159	IVW	1.49e-136	:	> 2.160 (2.033 to 2.295)	1.45e-05	
	159	Weighted-median	7.91e-63	H	• 2.008 (1.851 to 2.179)		
	159	MR-Presso	2.40e-59	:	> 2.158 (2.035 to 2.288)		
WC	122	MR-Egger	6.47e-11	⊢ <b>–</b>	1.966 (1.634 to 2.365)	4.40e-03	0.401
	122	IVW	3.30e-97	3	2.116 (1.972 to 2.270)	4.53e-03	
	122	Weighted-median	1.97e-37	H	2.023 (1.816 to 2.254)		
	122	MR-Presso	2.57e-42		2.122 (1.978 to 2.276)		
Hypertension	24	MR-Egger	3.82e-01	· . ●	• 0.410 (0.058 to 2.901)	5.51e-02	0.125
51	24	IVW	1.47e-02	·●		2.97e-02	
	24	Weighted-median	5.18e-01	<b>⊢↓</b> ●→→	1.228 (0.659 to 2.287)		
	24	MR-Presso	2.29e-02	·•			
SBP	155	MR-Egger	2.24e-01	•	1.005 (0.997 to 1.012)	1.00e-02	0.450
	155	IVW	1.96e-01	•	1.002 (0.999 to 1.005)	1.06e-02	
	155	Weighted-median	5.01e-01	•	1.002 (0.997 to 1.006)		
	155	MR-Presso	2.04e-01	<b>b</b>	1.002 (0.999 to 1.005)		
DBP	185	MR-Egger	9.84e-01	•	1.000 (0.985 to 1.015)	1.30e-07	0.710
	185	IVW	3.32e-01	•	0.997 (0.991 to 1.003)	1.61e-07	
	185	Weighted-median	2.74e-01		0.996 (0.989 to 1.003)		
	185	MR-Presso	2.86e-01	•	0.997 (0.991 to 1.003)		
HDL	66	MR-Egger	8.04e-01	Het I	0.990 (0.911 to 1.075)	1.83e-01	0.158
	66	IVW	2.78e-02	H <b>O</b> H	0.944 (0.896 to 0.994)	1.58e-01	
	66	Weighted-median	2.88e-01	H	0.961 (0.892 to 1.034)		
	66	MR-Presso	2.76e-02	•	0.943 (0.896 to 0.992)		
TG	89	MR-Egger	5.23e-01	H <mark>e</mark> H	1.041 (0.921 to 1.177)	3.19e-02	0.121
	89	IVW	1.81e-05	H <b>H</b> I	1.135 (1.071 to 1.203)	2.37e-02	
	89	Weighted-median	2.50e-02	He H	1.107 (1.013 to 1.209)		
	89	MR-Presso	7.50e-05	Iei	1.129 (1.066 to 1.195)		
Type 2 diabetes	22	MR-Egger	9.48e-01	· → →	• 1.102 (0.063 to 19.420)	4.74e-01	0.694
71	22	IVW	2.82e-02	·•	• 1.951 (1.074 to 3.545)	5.28e-01	
	22	Weighted-median	2.70e-01	⊢ <b>↓</b> →	• 1.600 (0.694 to 3.689)		
	22	MR-Presso	4.47e-02	<b>⊢</b> €>	1.828 (1.047 to 3.189)		
FBG	18	MR-Egger	3.46e-02	<b>⊢</b> •−-1	1.232 (1.032 to 1.471)	6.10e-01	0.057
	18	IVW	3.02e-01	H <b>e</b> H	1.043 (0.963 to 1.131)	3.86e-01	
	18	Weighted-median	8.03e-02	•	1.103 (0.988 to 1.230)		
	18	MR-Presso	2.74e-01	Her	1.043 (0.969 to 1.123)		
				0.5 1.0 1.5			
			+ Prof	ective factor Risk facto	r		

Protective factor Risk factor


**Figure 1. A** – Mendelian randomization results of the effect of metabolic syndrome and its components and GERD *BMI* – body mass index, *WC* – waist circumference, *SBP* – systolic blood pressure, *DBP* – diastolic blood pressure, *HDL* – high-density lipoprotein, *TG* – triglyceride, *FBG* – fasting blood glucose.

В								
Outcome	SNPs	Methods	P-value			OR (95% CI)	Heterogeneity. p-val	Pleiotropy. <i>p</i> -val
Metabolic	77	MR-Egger	2.80e-03		$  \longrightarrow$	> 2.098 (1.311 to 3.358)		0.465
syndrome	77	MN	2.56e-40		⊢∙⊣	1.765 (1.623 to 1.919)	1.36e-16	
	77	Weighted-median	1.66e-38		⊢●⊣	1.690 (1.562 to 1.830)		
	77	MR-Presso	1.58e-21		⊢●⊣	1.739 (1.601 to 1.888)		
BMI	76	MR-Egger	4.14e-03		·●->	• 1.726 (1.202 to 2.477)	5.96e-242	0.348
	76	IVW	4.65e-30		H <b>e</b> H	1.454 (1.363 to 1.550)	9.08e-245	
	76	Weighted-median	7.13e-62			1.340 (1.294 to 1.387)		
	76	MR-Presso	2.14e-18		Hert	1.441 (1.354 to 1.534)		
WC	76	MR-Egger	2.52e-02		<b>⊢</b>	1.398 (1.049 to 1.863)	7.63e-177	0.707
	76	IVW	3.52e-27		H <b>e</b> t	1.324 (1.258 to 1.393)	1.12e-176	
	76	Weighted-median	1.04e-52		•	1.245 (1.210 to 1.280)		
	76	MR-Presso	1.62e-17		H <b>e</b> l	1.318 (1.254 to 1.384)		
Hypertension	76	MR-Egger	4.63e-01	I	<b>b</b> i	1.017 (0.973 to 1.063)	2.45e-11 0.117	
	76	IVW	2.89e-37		•	1.053 (1.045 to 1.062)	5.71e-12	
	76	Weighted-median	7.28e-30		•	1.051 (1.042 to 1.060)		
	76	MR-Presso	1.97e-20		•	1.052 (1.044 to 1.060)		
SBP	55	MR-Egger	8.25e-01	<b>⊢</b> ●	;	• 0.801 (0.113 to 5.659)	6.29e-03	0.364
	55	IVW	6.08e-05			1.973 (1.415 to 2.749)	6.22e-03	
	55	Weighted-median	4.79e-03		<b>⊢</b> →	<ul> <li>1.835 (1.204 to 2.799)</li> </ul>		
	55	MR-Presso	1.05e-04		$\mapsto$	<ul> <li>2.025 (1.455 to 2.818)</li> </ul>		
DBP	51	MR-Egger	4.16e-01	<b>⊢</b> −●		• 0.608 (0.185 to 1.995)	3.86e-02	0.178
	51	IVW	1.21e-03		<b>⊢</b> ●−−1	1.378 (1.135 to 1.672)	3.01e-02	
	51	Weighted-median	1.97e-02		<b>⊢</b> •−−1	1.350 (1.049 to 1.737)		
	51	MR-Presso	2.50e-03		⊢•	1.360 (1.125 to 1.644)		
HDL	49	MR-Egger	1.13e-02	HOH		0.829 (0.721 to 0.953)	3.12e-02	0.942
	49	IVW	3.43e-65	•		0.833 (0.816 to 0.851)	3.87e-02	
	49	Weighted-median	2.07e-32	•		0.843 (0.819 to 0.867)		
	49	MR-Presso	4.09e-22	•		0.835 (0.817 to 0.852)		
TG	62	MR-Egger	1.28e-01		- <b>-</b> -	1.154 (0.962 to 1.384)	1.67e-06	0.763
	62	IVW	1.38e-44		•	1.187 (1.159 to 1.215)	2.34e-06	
	62	Weighted-median	5.36e-25		•	1.155 (1.124 to 1.187)		
	62	MR-Presso	6.02e-20		•	1.183 (1.153 to 1.212)		
Type 2 diabetes	76	MR-Egger	8.04e-03		•	1.047 (1.013 to 1.083)		0.217
	76	MN	5.65e-17		•	1.026 (1.020 to 1.032)	5.60e-19	
	76	Weighted-median	1.04e-16		•>	· 1.023 (1.017 to 1.028)		
	76	MR-Presso	4.97e-12		•	1.025 (1.019 to 1.031)		
FBG	65	MR-Egger	1.99e-01	•	•	1.102 (0.952 to 1.275)	7.31e-01	0.386
	65	IVW	1.15e-02		•	1.033 (1.007 to 1.060)	7.37e-01	
	65	Weighted-median	1.02e-01		•	1.031 (0.994 to 1.070)		
	65	MR-Presso	1.55e-03		•	1.036 (1.014 to 1.058)		
				0.5 1	.0 1.5			
			+			•		

#### Protective factor Risk factor

Figure 1. Cont. B – Mendelian randomization results of the effect of GERD and metabolic syndrome and its components

BMI – body mass index, WC – waist circumference, SBP – systolic blood pressure, DBP – diastolic blood pressure, HDL – highdensity lipoprotein, TG – triglyceride, FBG – fasting blood glucose.



**Figure 2.** Causal relationships between metabolic syndrome (MetS), its components, and the risk of gastroesophageal reflux disease (GERD) development estimated using the multivariable Mendelian randomization-inverse variance weighted (MVMR-IVW) method valuable insights into causal relationships, it does not elucidate the underlying biological mechanisms.

In conclusion, our UVMR and MVMR analyses identified causal associations between MetS, its components, and GERD development risk. However, further studies are needed to validate the role of MetS and its components in regulating GERD development. Our findings suggest that MetS may serve as an early intervention target for preventing GERD.

## Acknowledgments

Tao He and Xiaoling Geng have contributed equally to this work.

#### Funding

No external funding.

#### Ethical approval

Not applicable.

## **Conflict of interest**

The authors declare no conflict of interest.

## References

- 1. Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal reflux disease: a review. JAMA 2020; 324: 2536-47.
- 2. Becher A, El-Serag H. Systematic review: the association between symptomatic response to proton pump inhibitors and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2011; 34: 618-27.
- Kumari R, Kumar S, Kant R. An update on metabolic syndrome: metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab Syndr 2019; 13: 2409-17.
- 4. Patti AM, Al-Rasadi K, Giglio RV, et al. Natural approaches in metabolic syndrome management. Arch Med Sci 2018; 14: 422-41.
- 5. Hirode G, Wong RJ. Trends in the prevalence of metabolic syndrome in the United States, 2011-2016. JAMA 2020; 323: 2526-8.
- 6. Drahos J, Ricker W, Parsons R, Pfeiffer RM, Warren JL, Cook MB. Metabolic syndrome increases risk of Barrett esophagus in the absence of gastroesophageal reflux: an analysis of SEER-Medicare Data. J Clin Gastroenterol 2015; 49: 282-8.
- 7. Kallel L, Bibani N, Fekih M, et al. Metabolic syndrome is associated with gastroesophageal reflux disease based on a 24-hour ambulatory pH monitoring. Dis Esophagus 2011; 24: 153-9.
- Smith GD, Ebrahim S. Mendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003; 32: 1-22.
- 9. Heng D, Ma S, Lee JJ, et al. Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 2006; 186: 367-73.
- Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27: 1133-63.

- 11. Lind L. Genome-wide association study of the metabolic syndrome in UK Biobank. Metab Syndr Relat Disord 2019; 17: 505-11.
- 12. Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med 2020; 17: e1003062.
- 13. Manning AK, Hivert MF, Scott RA, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 2012; 44: 659-69.
- Evangelou E, Warren HR, Mosen-Ansorena D, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet 2018; 50: 1412-25.
- 15. Ong JS, An J, Han X, et al. Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. Gut 2022; 71: 1053-61.
- 16. Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature 2015; 526: 68-74.
- 17. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. Int J Epidemiol 2011; 40: 755-64.
- Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics (Oxford, England) 2019; 35: 4851-3.
- Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013; 42: 1497-501.
- 20. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013; 37: 658-65.
- 21. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017; 32: 377-89.
- 22. Verbanck M, Chen CY, Neale B, Do R. Publisher Correction: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature Genet 2018; 50: 1196.
- 23. Cottam DR, Mattar SG, Barinas-Mitchell E, et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg 2004; 14: 589-600.
- 24. Jin Z, Wang Z, Wang R, et al. Global burden and epidemic trends of gout attributable to high body mass index from 1990 to 2019. Arch Med Sci 2024; 20: 71-80.
- 25. Mirrakhimov E, Bektasheva E, Isakova J, et al. Association of leptin receptor gene Gln223Arg polymorphism with insulin resistance and hyperglycemia in patients with metabolic syndrome. Arch Med Sci 2024; 20: 54-60.
- 26. Nomura M, Tashiro N, Watanabe T, et al. Association of symptoms of gastroesophageal reflux with metabolic syndrome parameters in patients with endocrine disease. ISRN Gastroenterol 2014; 2014: 863206.
- Wu P, Ma L, Dai GX, et al. The association of metabolic syndrome with reflux esophagitis: a case-control study. Neurogastroenterol Motil 2011; 23: 989-94.
- Fu S, Xu M, Zhou H, Wang Y, Tan Y, Liu D. Metabolic syndrome is associated with higher rate of gastroesophageal reflux disease: a meta-analysis. Neurogastroenterol Motil 2022; 34: e14234.